Siemens Healthineers meets Q3 sales expectations, raises guidance

Siemens Healthineers reported third-quarter revenue of €5.66 billion, slightly surpassing analyst expectations and marking a 7.6% comparable increase, largely driven by strong growth in China. The medical technology firm also raised its full-year comparable revenue growth outlook to 5.5-6% and adjusted basic EPS guidance to €2.30-2.45, citing a new EU-U.S. trade agreement. This robust performance was further underscored by a 54% year-over-year surge in free cash flow to €844 million, indicating strong profitability despite a volatile geopolitical environment.

Analysis

Siemens Healthineers demonstrated strong operational performance in its third quarter, with revenue reaching €5.66 billion, narrowly exceeding the analyst consensus of €5.61 billion. This represents a 7.6% year-over-year comparable growth, primarily fueled by a significant rebound in its China business following declines in the prior year. The company's fundamental health is further underscored by a 54% surge in free cash flow to €844 million, indicating robust profitability and cash generation. Citing a new EU-U.S. trade agreement, management has raised its full-year 2025 revenue growth guidance to a range of 5.5% to 6.0% and tightened its adjusted EPS forecast to €2.30-€2.45. This updated guidance signals increased confidence, though CEO Bernd Montag tempered the positive outlook by noting the persistence of a highly volatile geopolitical environment.

Key Decisions for Investors

• The combination of a revenue beat, a 54% increase in free cash flow, and raised full-year guidance supports a bullish thesis on the company's operational execution and financial health.
• Investors should monitor the performance of the China business in subsequent quarters, as its sustained momentum is a critical driver for achieving the new, more ambitious revenue targets.
• Despite the positive results, the CEO's caution on geopolitical volatility suggests that investors should remain attentive to macroeconomic and trade policy developments as a primary risk factor to the outlook.